ACADIA PHARMACEUTICALS INC (ACAD)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch ACAD
See up to 3 months of ACAD. The 7-day demo opens the 1M and 3M ranges and puts ACAD on your watchlist.
Start 7-day demoLatest ACAD insider trades
About ACADIA PHARMACEUTICALS INC (ACAD)
The SEC lists ACADIA PHARMACEUTICALS INC under CIK 0001070494, in pharmaceutical preparations. It is grouped with Health Care companies on this site.
ACAD Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 36,699 | $1.02M |
| Option exercise | 6 | 104,826 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ACAD insider transactions (Form 4)
6853 Form 4 filings on record, the earliest from Oct 15, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| James M. Daly | Open-market sale | Common Stock | 30,000 | $22.37 footnote F1 | $671K | |
| ||||||
| Mark C. Schneyer - Officer | Grant or award | Common Stock | 6,815 | $0.00 | - | |
| Mark C. Schneyer - Officer | Open-market sale | Common Stock | 3,498 | $23.65 | $83K | |
| Elizabeth A. Garofalo | Open-market sale | Common Stock | 1,600 | $25.98 | $42K | |
| Mark C. Schneyer - Officer | Open-market sale | Common Stock | 22,000 | $25.18 | $554K | |
| Laura Brege | Open-market sale | Common Stock | 14,446 | $21.78 | $315K | |
| Daniel B. Soland | Option exercise | Common Stock | 9,387 | - | - | |
| Daniel B. Soland | Option exercise | Restricted Stock Units | 9,387 | $0.00 | - | |
| Daniel B. Soland | Grant or award | Director Stock Options (Right to Buy) | 13,793 | $0.00 | - | |
| Daniel B. Soland | Grant or award | Restricted Stock Units | 8,107 | $0.00 | - | |
| Adora Ndu | Option exercise | Common Stock | 9,387 | - | - | |
| Adora Ndu | Option exercise | Restricted Stock Units | 9,387 | $0.00 | - | |
| Adora Ndu | Grant or award | Director Stock Options (Right to Buy) | 13,793 | $0.00 | - | |
| Adora Ndu | Grant or award | Restricted Stock Units | 8,107 | $0.00 | - | |
| Edmund Harrigan | Option exercise | Common Stock | 9,387 | - | - | |
| Edmund Harrigan | Option exercise | Restricted Stock Units | 9,387 | $0.00 | - | |
| Edmund Harrigan | Grant or award | Director Stock Options (Right to Buy) | 13,793 | $0.00 | - | |
| Edmund Harrigan | Grant or award | Restricted Stock Units | 8,107 | $0.00 | - | |
| Elizabeth A. Garofalo | Option exercise | Common Stock | 9,387 | - | - | |
| Elizabeth A. Garofalo | Option exercise | Restricted Stock Units | 9,387 | $0.00 | - | |
| Elizabeth A. Garofalo | Grant or award | Director Stock Options (Right to Buy) | 13,793 | $0.00 | - | |
| Elizabeth A. Garofalo | Grant or award | Restricted Stock Units | 8,107 | $0.00 | - | |
| James M. Daly | Option exercise | Common Stock | 9,387 | - | - | |
| James M. Daly | Option exercise | Restricted Stock Units | 9,387 | $0.00 | - | |
| James M. Daly | Grant or award | Director Stock Options (Right to Buy) | 13,793 | $0.00 | - | |
| James M. Daly | Grant or award | Restricted Stock Units | 8,107 | $0.00 | - | |
| Laura Brege | Option exercise | Common Stock | 9,387 | - | - | |
| Laura Brege | Option exercise | Restricted Stock Units | 9,387 | $0.00 | - | |
| Laura Brege | Grant or award | Director Stock Options (Right to Buy) | 13,793 | $0.00 | - | |
| Laura Brege | Grant or award | Restricted Stock Units | 8,107 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Common Stock | 16,214 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Common Stock | 16,214 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non- Qualified Stock Option (right to buy) | 27,586 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non- Qualified Stock Option (right to buy) | 27,586 | $0.00 | - | |
| Mark C. Schneyer - Officer | Open-market sale | Common Stock | 2,000 | $25.00 | $50K | |
| James Kihara - Officer | Open-market sale | Common Stock | 2,000 | $25.00 | $50K | |
| James Kihara - Officer | Open-market sale | Common Stock | 2,000 | $20.00 | $40K | |
| James Kihara - Officer | Option exercise | Common Stock | 2,596 | - | - | |
| James Kihara - Officer | Open-market sale | Common Stock | 1,327 | $14.60 | $19K | |
| James Kihara - Officer | Option exercise | Restricted Stock Units | 2,596 | $0.00 | - | |
| Mark C. Schneyer - Officer | Option exercise | Common Stock | 6,815 | - | - | |
| Mark C. Schneyer - Officer | Open-market sale | Common Stock | 3,498 | $14.60 | $51K | |
| Mark C. Schneyer - Officer | Option exercise | Restricted Stock Units | 6,815 | $0.00 | - | |
| Mark C. Schneyer - Officer | Option exercise | Common Stock | 5,275 | - | - | |
| Mark C. Schneyer - Officer | Open-market sale | Common Stock | 2,708 | $14.82 | $40K | |
| Mark C. Schneyer - Officer | Option exercise | Restricted Stock Units | 5,275 | $0.00 | - | |
| James Kihara - Officer | Option exercise | Common Stock | 2,010 | - | - | |
| James Kihara - Officer | Open-market sale | Common Stock | 1,028 | $14.82 | $15K | |
| James Kihara - Officer | Option exercise | Restricted Stock Units | 2,010 | $0.00 | - | |
| Thomas Garner - Officer | Grant or award | Stock Option (Right to Buy) | 235,849 | $0.00 | - | |
| Thomas Garner - Officer | Grant or award | Restricted Stock Units | 45,372 | $0.00 | - | |
| Brendan Teehan - Officer | Option exercise | Common Stock | 9,913 | - | - | |
| Brendan Teehan - Officer | Option exercise | Common Stock | 9,913 | - | - | |
| Brendan Teehan - Officer | Open-market sale | Common Stock | 10,329 | $16.81 | $174K | |
| Brendan Teehan - Officer | Option exercise | Restricted Stock Units | 9,913 | $0.00 | - | |
| Brendan Teehan - Officer | Option exercise | Restricted Stock Units | 9,913 | $0.00 | - | |
| James Kihara - Officer | Option exercise | Common Stock | 3,965 | - | - | |
| James Kihara - Officer | Option exercise | Common Stock | 3,965 | - | - | |
| James Kihara - Officer | Open-market sale | Common Stock | 4,073 | $16.81 | $68K | |
| James Kihara - Officer | Option exercise | Restricted Stock Units | 3,965 | $0.00 | - | |
| James Kihara - Officer | Option exercise | Restricted Stock Units | 3,965 | $0.00 | - | |
| Mark C. Schneyer - Officer | Option exercise | Common Stock | 9,913 | - | - | |
| Mark C. Schneyer - Officer | Option exercise | Common Stock | 9,913 | - | - | |
| Mark C. Schneyer - Officer | Open-market sale | Common Stock | 10,259 | $16.81 | $172K | |
| Mark C. Schneyer - Officer | Option exercise | Restricted Stock Units | 9,913 | $0.00 | - | |
| Mark C. Schneyer - Officer | Option exercise | Restricted Stock Units | 9,913 | $0.00 | - | |
| Adora Ndu | Option exercise | Common Stock | 4,381 | - | - | |
| Adora Ndu | Option exercise | Restricted Stock Units | 4,381 | $0.00 | - | |
Item 7.01, 8.01, 9.01
Item 8.01, 9.01
Item 2.02, 9.01
Item 5.02, 5.07, 9.01
Recent ACAD Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Schneyer Mark C. | Officer | 5,849 | $159K | View on EDGAR | |
| - | - | - | - |
ACAD insider trading FAQ
What is the latest insider trade for ACAD?
ACADIA PHARMACEUTICALS INC (ACAD) had 2 insider filings in the last 90 days, with the most recent on 2026-08-07. The full record for ACAD runs to 53 Form 4 filings, the earliest from 2024-10-15. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ACAD stock?
No insider purchases of ACAD were filed in the last 90 days.
How many insiders are selling ACAD stock?
5 insider sales of ACAD were filed in the last 90 days, totaling $1.02M.
Where can I see ACAD SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ACAD Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Mark C. Schneyer view on EDGAR
- - Elizabeth H.Z. Thompson view on EDGAR
- - James Kihara view on EDGAR
- - BAKER BROS. ADVISORS LP view on EDGAR
- - Edmund Harrigan view on EDGAR
- - Adora Ndu view on EDGAR
- - Laura Brege view on EDGAR
- - Jonathan Poole view on EDGAR
- - Elizabeth A. Garofalo view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ACAD's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ACAD with a 7-day demo
- ACAD on your watchlist
- Every ACAD Form 4 filing on record
- Up to 3 months of ACAD price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
